The Traderszone Network

Published in TZ Latest News 31 July, 2017 by The TZ Newswire Staff

The rollercoaster ride that led to Dynavax stock skyrocketing 74%

Safety concerns held the company’s hepatitis B vaccine from approval, but a FDA safety committee just voted in its favor.
read more